Current clinical practice guidelines recommend the antifibrotic agent nintedanib for patients with PPF who have failed standard management for fibrotic ILD. The INBUILD clinical trial suggests that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients with chronic fibrosing ILD. In addition, nintedanib may still be effective when used in combination with immunomodulatory therapies.
Learn more about medication for PF-ILD.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Fast Five Quiz: Interstitial Lung Disease Progressive Fibrosing Management - Medscape - Mar 06, 2023.